miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial

201945 citationsJournal Articlebronze Open Access

Authors

Our study validates the role of miR-31-3p as potential predictive biomarker of selection for anti-EGFR mAbs.

No povertyGood health and well-being

Published in: Clinical Cancer Research

Volume 25, Issue 13, pp. 3830-3838

Field-Weighted Citation Impact: 2.82